Palit, S. A. L., Dorp, J. v., Vis, D., Lieftink, C., Linder, S., Beijersbergen, R., . . . Heijden, M. S. v. d. (2021). A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Nature Portfolio.
Cita Chicago Style (17a ed.)Palit, Sander A. L., Jeroen van Dorp, Daniel Vis, Cor Lieftink, Simon Linder, Roderick Beijersbergen, Andries M. Bergman, Wilbert Zwart, y Michiel S. van der Heijden. A Kinome-centered CRISPR-Cas9 Screen Identifies Activated BRAF to Modulate Enzalutamide Resistance with Potential Therapeutic Implications in BRAF-mutated Prostate Cancer. Nature Portfolio, 2021.
Cita MLA (8a ed.)Palit, Sander A. L., et al. A Kinome-centered CRISPR-Cas9 Screen Identifies Activated BRAF to Modulate Enzalutamide Resistance with Potential Therapeutic Implications in BRAF-mutated Prostate Cancer. Nature Portfolio, 2021.